13C-phenylalanine breath test and serum biopterin in schizophrenia, bipolar disorder and major depressive disorder
| Autor: | Kotaro Hattori, Masahiro Kajiwara, Yuji Ozeki, Shinsuke Hidese, Hiroaki Hori, Toshiya Teraishi, Miho Ota, Hiroshi Kunugi, Teruhiko Higuchi, Daimei Sasayama, Ikki Ishida, Yasuhiro Kajiwara, Junko Matsuo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Phenylalanine hydroxylase Biopterin Phenylalanine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine mental disorders medicine Bipolar disorder Biological Psychiatry Breath test medicine.diagnostic_test biology business.industry Tetrahydrobiopterin medicine.disease 030227 psychiatry Psychiatry and Mental health Endocrinology chemistry Schizophrenia biology.protein Major depressive disorder business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Psychiatric Research. 99:142-150 |
| ISSN: | 0022-3956 |
| Popis: | Phenylalanine is required for the synthesis of the neurotransmitters dopamine, noradrenaline, and adrenaline. The rate-limiting step for phenylalanine metabolism is catalyzed by phenylalanine hydroxylase (PAH) and its cofactor tetrahydrobiopterin. We aimed to detect altered phenylalanine metabolism in major psychiatric disorders using the l -[1-13C]phenylalanine breath test (13C-PBT) and serum biopterin levels. We also investigated association of PAH mutations with schizophrenia and phenylalanine metabolism. 13C-phenylalanine (100 mg) was orally administered, and the breath 13CO2/12CO2 ratio was monitored for 120 min in four groups: 103 patients with schizophrenia (DSM-IV), 39 with bipolar disorder, 116 with major depressive disorder (MDD), and 241 healthy controls. Serum biopterin levels were measured by high performance liquid chromatography. Mutation screening of PAH exons was performed by direct sequencing in 46 schizophrenia patients. Association analysis was performed using six tag single nucleotide polymorphisms and the PAH Arg53His mutation by TaqMan assays in 616 schizophrenia patients and 1194 healthy controls. Analyses of covariance controlling for age, sex, and body weight showed that the index for the amount of exhaled 13CO2 was significantly lower in the schizophrenia group than in the other three groups (all p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect